137 related articles for article (PubMed ID: 38206158)
1. Comparing the Efficacy and Tolerability of Moderate to Severe Hyperpigmentation and Skin Unevenness.
Callender VD; Orlinsky D; Simmons-O'Brien E; Nwade NC; Rhodes T; Byrd AS
J Drugs Dermatol; 2024 Jan; 23(1):1260-1265. PubMed ID: 38206158
[TBL] [Abstract][Full Text] [Related]
2. A Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia.
Wang J; Fabi S; Robinson D; Bajaj S; Geronemus R; Bell M; Widgerow A
J Drugs Dermatol; 2023 Apr; 22(4):333-338. PubMed ID: 37026875
[TBL] [Abstract][Full Text] [Related]
3. Brightening and Improvement of Facial Skin Quality in Healthy Female Subjects With Moderate Hyperpigmentation or Dark Spots and Moderate Facial Aging.
Serra M; Bohnert K; Narda M; Granger C; Sadick N
J Drugs Dermatol; 2018 Dec; 17(12):1310-1315. PubMed ID: 30586263
[TBL] [Abstract][Full Text] [Related]
4. Topical Treatments for Melasma and Post-inflammatory Hyperpigmentation.
Sadick N; Pannu S; Abidi Z; Arruda S
J Drugs Dermatol; 2023 Nov; 22(11):1118-1123. PubMed ID: 37943277
[TBL] [Abstract][Full Text] [Related]
5. Combination of In-Office Chemical Peels With a Topical Comprehensive Pigmentation Control Product in Skin of Color Subjects With Facial Hyperpigmentation.
Downie J; Schneider K; Goberdhan L; Makino ET; Mehta RC
J Drugs Dermatol; 2017 Apr; 16(4):301-306. PubMed ID: 28403262
[TBL] [Abstract][Full Text] [Related]
6. Pigmentation control in pregnancy-induced melasma: Clinical assessment of a non-hydroquinone, non-retinol pigment-correcting serum.
Makino ET; Jiang LI; Stephens TJ; Mikati M; Mehta RC
J Cosmet Dermatol; 2022 Nov; 21(11):5739-5746. PubMed ID: 35708506
[TBL] [Abstract][Full Text] [Related]
7. Topical Stabilized Cysteamine as a New Treatment for Hyperpigmentation Disorders: Melasma, Post-Inflammatory Hyperpigmentation, and Lentigines.
Desai S; Hartman C; Grimes P; Shah S
J Drugs Dermatol; 2021 Dec; 20(12):1276-1279. PubMed ID: 34898155
[TBL] [Abstract][Full Text] [Related]
8. Extension Phase of a Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia.
Wang JV; Fabi SG; Robinson DM; Bajaj S; Geronemus RG; Bell M; Robison T; Widgerow AD
J Drugs Dermatol; 2024 Jan; 23(1):1266-1270. PubMed ID: 38206144
[TBL] [Abstract][Full Text] [Related]
9. Randomized, Double-Blinded, Split-Face Study Comparing the Efficacy and Tolerability of Two Topical Products for Melasma.
Kaufman BP; Alexis AF
J Drugs Dermatol; 2020 Sep; 19(9):822-827. PubMed ID: 33026755
[TBL] [Abstract][Full Text] [Related]
10. Cysteamine Isobionic-Amide Complex Versus Kligman's Formula for the Treatment of Melasma: Equal Efficacy and Rapid Onset of Action.
Sachdev M; Grimes PE; Callender V; Hartman CL; Taylor SC; Elbuluk N; Badawi A; Funasaka Y; Lim J; Ng CY; Desai SR
J Drugs Dermatol; 2024 Feb; 23(2):9-16. PubMed ID: 38306138
[TBL] [Abstract][Full Text] [Related]
11. Single blind, randomized, controlled trial of a lightening product with and without iontophoresis versus tretinoin and vehicle for hyperpigmentation.
Wanner M; Houston N; Javorsky E; Yuan M; Alora-Palli M; Kimball AB
J Drugs Dermatol; 2015 Jan; 14(1):13-8. PubMed ID: 25607903
[TBL] [Abstract][Full Text] [Related]
12. Novel skin brightener used as monotherapy for moderate melasma in skin of color.
Grimes PE
J Drugs Dermatol; 2014 Mar; 13(3):364-6. PubMed ID: 24595584
[TBL] [Abstract][Full Text] [Related]
13. Clinical Evaluation of a 4% Hydroquinone + 1% Retinol Treatment Regimen for Improving Melasma and Photodamage in Fitzpatrick Skin Types III-VI.
Rendon MI; Barkovic S
J Drugs Dermatol; 2016 Nov; 15(11):1435-1441. PubMed ID: 28095558
[TBL] [Abstract][Full Text] [Related]
14. Comparative study of hydroquinone-free and hydroquinone-based hyperpigmentation regimens in treating facial hyperpigmentation and photoaging.
Fabi SG; Goldman MP
J Drugs Dermatol; 2013 Mar; 12(3):S32-7. PubMed ID: 23545931
[TBL] [Abstract][Full Text] [Related]
15. A comparative study of topical 5% cysteamine versus 4% hydroquinone in the treatment of facial melasma in women.
Lima PB; Dias JAF; Cassiano D; Esposito ACC; Bagatin E; Miot LDB; Miot HA
Int J Dermatol; 2020 Dec; 59(12):1531-1536. PubMed ID: 32864760
[TBL] [Abstract][Full Text] [Related]
16. Investigator-Blinded, Single-Center Study to Evaluate the Efficacy and Tolerability of a 4% Hydroquinone Skin Care System Plus 0.02% Tretinoin Cream in Mild-to-Moderate Melasma and Photodamage.
Rendon M; Dryer L
J Drugs Dermatol; 2016 Apr; 15(4):466-75. PubMed ID: 27050702
[TBL] [Abstract][Full Text] [Related]
17. An Advanced, Physician-Strength Retinol Peel Improves Signs of Aging and Acne Across a Range of Skin Types Including Melasma and Skin of Color.
Sadick N; Edison BL; John G; Bohnert KL; Green B
J Drugs Dermatol; 2019 Sep; 18(9):918-923. PubMed ID: 31524348
[TBL] [Abstract][Full Text] [Related]
18. Effect of a Tranexamic Acid, Kojic Acid, and Niacinamide Containing Serum on Facial Dyschromia: A Clinical Evaluation.
Desai S; Ayres E; Bak H; Manco M; Lynch S; Raab S; Du A; Green D; Skobowiat C; Wangari-Talbot J; Zheng Q
J Drugs Dermatol; 2019 May; 18(5):454-459. PubMed ID: 31141852
[TBL] [Abstract][Full Text] [Related]
19. A Randomized, Investigator-Blinded Comparison of Two Topical Regimens in Fitzpatrick Skin Types III-VI With Moderate to Severe Facial Hyperpigmentation.
Vanaman Wilson MJ; Jones IT; Bolton J; Larsen L; Wu DC; Goldman MP
J Drugs Dermatol; 2017 Nov; 16(11):1127-1132. PubMed ID: 29141061
[TBL] [Abstract][Full Text] [Related]
20. Thiamidol containing treatment regimens in facial hyperpigmentation: An international multi-centre approach consisting of a double-blind, controlled, split-face study and of an open-label, real-world study.
Philipp-Dormston WG; Vila Echagüe A; Pérez Damonte SH; Riedel J; Filbry A; Warnke K; Lofrano C; Roggenkamp D; Nippel G
Int J Cosmet Sci; 2020 Aug; 42(4):377-387. PubMed ID: 32390164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]